RESPIRATORY AND NUTRITIONAL OUTCOMES DURING SMN-DIRECTED THERAPY IN PATIENTS WITH 5Q-SPINAL MUSCULAR ATROPHY
Keywords:
patients, respiratory, motor, nutritional, group, treatment, earlier, outcomes, therapy, includedAbstract
Spinal muscular atrophy (SMA) is a progressive hereditary neuromuscular disorder caused predominantly by biallelic pathogenic variants of the SMN1 gene. Deficiency of functional survival motor neuron protein results in progressive degeneration of α-motor neurons, producing symmetrical muscle weakness, muscular atrophy and progressive loss of motor abilities. Although impairment of motor function represents the most evident clinical manifestation of SMA, respiratory, bulbar and nutritional complications are also major determinants of disease burden and long-term prognosis.References
During 12 months of SMN-directed therapy, patients who began
treatment earlier demonstrated a tendency toward better respiratory stability and more
favorable nutritional outcomes than patients with delayed treatment initiation. The
proportions of patients remaining free from permanent ventilation, severe respiratory
hospitalization and nutritional deterioration were numerically higher in the earliertreatment group. However, unlike motor outcomes, most differences in respiratory and
nutritional endpoints did not reach statistical significance. These findings support a
comprehensive model of SMA management in which early pathogenetic treatment is
combined with continuous multidisciplinary respiratory, nutritional, neurological and
rehabilitative care.